ValiRx PLC Result of General Meeting (6097V)

TIDMVAL

RNS Number : 6097V

ValiRx PLC

24 July 2018

---

VALIRX PLC

("ValiRx" or the "Company")

RESULT OF GENERAL MEETING

London, UK., 24 July 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that at a General Meeting of the Company held earlier today, all resolutions were passed.

Voting on the resolutions was as follows:-

 
 Resolution                                             For          Against     Withheld 
              Authorise the directors to allot 
 1             ordinary shares                          43,324,692   1,538,486   654 
             ----------------------------------------  -----------  ----------  ---------- 
              Empower the directors to allot ordinary 
 2             shares on a non pre-emptive basis        37,464,314   2,940,640   1,649,012 
             ----------------------------------------  -----------  ----------  ---------- 
 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

*** ENDS ***

For more information, please contact:

 
 ValiRx plc                                 Tel: [phone] 
                                             www.valirx.com 
 Dr Satu Vainikka, Chief Executive          Tel: [phone] 
 Tarquin Edwards, Head of Communications.   Tel: [phone] 
                                             364 
                                             [e-mail] 
 Cairn Financial Advisers LLP (Nominated    Tel: [phone] 
  Adviser) 
  Liam Murray / Jo Turner 
 Novum Securities Limited                   Tel: [phone] 
  Colin Rowbury 
 

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

ROMBBGDRDBDBGIS

(END) Dow Jones Newswires

July 24, 2018 07:17 ET (11:17 GMT)